Aclaris Therapeutics, Inc. (ACRS) Market Cap & Valuation Ratios
Aclaris Therapeutics, Inc. (ACRS) has a market cap of $552.0M and a price-to-sales ratio of 67.2, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ACRSAclaris Therapeutics, Inc.Follow ACRS — free
—
Price chart with a free account
- Market cap
- 552.0M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
Peers
biotechnology · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| ACRS | 0.6 | — | 56.0 | — | -11.3% | -51% | — | -82% |
| CADL | 0.6 | — | — | — | -9.3% | — | — | — |
| CRMD | 0.6 | 3.8 | 1.1 | 2.0 | — | +281% | 47% | 57% |
| SGMT | 0.6 | — | — | — | -7.0% | — | — | -59% |
| CLYM | 0.6 | — | — | — | -9.3% | — | — | -36% |
| IMMX | 0.6 | — | — | — | -6.7% | — | — | — |
| ZVRA | 0.6 | 10.7 | 2.7 | 4.3 | 5.6% | +119% | 61% | 68% |
| DBVT | 0.6 | — | 80.2 | — | — | +29% | — | — |
| MDXG | 0.6 | 97.8 | 1.3 | 5.7 | 7.8% | -2% | 2% | 4% |
| OLMA | 0.6 | — | — | — | — | — | — | -65% |
| CTMX | 0.5 | — | 9.6 | — | — | -87% | -476% | -49% |
| Median of these 10 | 10.7 | 2.7 | 4.3 | -6.9% | +29% | 25% | -36% |
; EV/Sales 56.0 vs. 2.7.
Growth vs. price
each dot a company · hover or tap for valuesACRS and CADL and SGMT and CLYM and IMMX and DBVT and OLMA and CTMX have no P/E (earnings not positive) and are left out · hover or tap a dot for values.
Aclaris Therapeutics, Inc. — questions
- What is Aclaris Therapeutics, Inc.'s market cap?
- $552.0M.
- What is Aclaris Therapeutics, Inc.'s price-to-sales ratio?
- 67.2.
Every figure on this page comes from Aclaris Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.